|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15601561156215631564156515661567156815691570...15771578» |
- | Enrollment open, Surgery, Metastases: STRASS: Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma (clinicaltrials.gov) - Jun 10, 2013
P3, N=256, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting
- | Torisel (temsirolimus) / Pfizer
Enrollment open, Stroma: COMTT: Caphosol in Oral Mucositis Due to Targeted Therapy (clinicaltrials.gov) - Jun 10, 2013
P3, N=60, Recruiting, Sponsor: Christine B Boers-Doets
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Votrient (pazopanib) / Novartis, BeiGene
Trial completion: Study of Pazopanib and Ixabepilone in Patients With Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=31, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Mekinist (trametinib) / Novartis, BeiGene, Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Combination therapy, Metastases: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (clinicaltrials.gov) - Jun 9, 2013
P1, N=111, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed N=61 --> 111
- Iclusig (ponatinib) / Takeda, Otsuka
New P2 trial, Stroma, Metastases: A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Jun 9, 2013
P2, N=45, Suspended, Sponsor: Ariad Pharmaceuticals
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, IO biomarker, Surgery: acns0333: Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov) - Jun 9, 2013
P3, N=70, Active, not recruiting, Sponsor: Children's Oncology Group
N=61 --> 111 Recruiting --> Active, not recruiting
- || Sutent (sunitinib) / Pfizer
Enrollment change, Stroma: Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib (clinicaltrials.gov) - Jun 6, 2013
P=N/A, N=322, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting N=500 --> 322
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Roche
New P2 trial, Surgery: RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov) - Jun 5, 2013
P2, N=48, Recruiting, Sponsor: St. Jude Children's Research Hospital
- zoledronic acid / Generic mfg.
Enrollment change, Metastases: Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=24, Completed, Sponsor: Children's Oncology Group
N=500 --> 322 N=30 --> 24
- | temozolomide / Generic mfg.
Enrollment change: Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov) - Jun 4, 2013
P3, N=1173, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
N=30 --> 24 N=834 --> 1173
- lenalidomide / Generic mfg.
Enrollment closed: Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma (clinicaltrials.gov) - Jun 3, 2013
P1/2, N=46, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=834 --> 1173 Recruiting --> Active, not recruiting
- Trial completion: Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer (clinicaltrials.gov) - Jun 3, 2013
P=N/A, N=70, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- imatinib / Generic mfg.
New P2 trial, Surgery, Metastases: Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy (clinicaltrials.gov) - May 29, 2013
P2, N=50, Recruiting, Sponsor: Chang Gung Memorial Hospital
- Trial termination: Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: (clinicaltrials.gov) - May 28, 2013
P=N/A, N=8, Terminated, Sponsor: State University of New York - Upstate Medical University
Active, not recruiting --> Completed Enrolling by invitation --> Terminated; low enrollment low enrollment
- Enrollment closed, Biopsy: Huntsman Biopsy Study (clinicaltrials.gov) - May 28, 2013
P=N/A, N=100, Active, not recruiting, Sponsor: State University of New York - Upstate Medical University
Enrolling by invitation --> Terminated; low enrollment low enrollment Recruiting --> Active, not recruiting
- | Trial completion, Trial initiation date: Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma (clinicaltrials.gov) - May 28, 2013
P=N/A, N=17, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Initiation date: Apr 2002 --> Apr 2005 | Recruiting --> Completed
- Enrollment change: Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma (clinicaltrials.gov) - May 28, 2013
P=N/A, N=17, Completed, Sponsor: Children's Oncology Group
Initiation date: Apr 2002 --> Apr 2005 | Recruiting --> Completed N=65 --> 17
- Avastin (bevacizumab) / Roche
Enrollment open: Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - May 28, 2013
P2, N=178, Recruiting, Sponsor: Radiation Therapy Oncology Group
N=65 --> 17 Not yet recruiting --> Recruiting
- | Trial completion: Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma (clinicaltrials.gov) - May 28, 2013
P=N/A, N=17, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Completed
- trebananib (AMG 386) / Amgen
Trial suspension: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) - May 27, 2013
P2, N=55, Suspended, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed Recruiting --> Suspended
- | Tasigna (nilotinib) / Novartis, Inhibikase
New P2 trial: Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment (clinicaltrials.gov) - May 27, 2013
P2, N=15, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- | temozolomide / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Combination therapy: Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov) - May 27, 2013
P2, N=83, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Enrollment closed: High Precision RT For Soft-Tissue Sarcoma (clinicaltrials.gov) - May 27, 2013
P2, N=70, Active, not recruiting, Sponsor: University Health Network, Toronto
Recruiting --> Suspended Recruiting --> Active, not recruiting
- |||| Avastin (bevacizumab) / Roche
Trial completion: Ph II Bevacizumab + Etoposide for Pts w Recurrent MG (clinicaltrials.gov) - May 27, 2013
P2, N=59, Completed, Sponsor: Duke University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- taladegib (ENV 101) / Endeavor BioMed
Trial initiation date: A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma (clinicaltrials.gov) - May 22, 2013
P1, N=0, Withdrawn, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Initiation date: Apr 2013 --> Jul 2013
- | Votrient (pazopanib) / Novartis, BeiGene
New P2 trial, Metastases: A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 22, 2013
P2, N=120, Recruiting, Sponsor: Hannover Medical School
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
New P2 trial: Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma (clinicaltrials.gov) - May 21, 2013
P2, N=49, Recruiting, Sponsor: National Cancer Institute (NCI)
- | imatinib / Generic mfg., everolimus / Generic mfg.
Enrollment change, Stroma: Radix: Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (clinicaltrials.gov) - May 20, 2013
P4, N=27, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Apr 2013 --> Jul 2013 N=53 --> 27
- Oncophage (Heat Shock Protein Peptide Complex-96) / Agenus, Avastin (bevacizumab) / Roche
Enrollment open, Surgery: Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery (clinicaltrials.gov) - May 20, 2013
P2, N=222, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
N=53 --> 27 Not yet recruiting --> Recruiting
- | sunitinib / Generic mfg.
Enrollment closed, Stroma: Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT (clinicaltrials.gov) - May 20, 2013
P3, N=80, Active, not recruiting, Sponsor: Asan Medical Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | imatinib / Generic mfg., everolimus / Generic mfg.
Trial completion, Stroma: Radix: Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (clinicaltrials.gov) - May 20, 2013
P4, N=27, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors (clinicaltrials.gov) - May 19, 2013
P=N/A, N=750, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=500 --> 750
- | vincristine / Generic mfg.
Enrollment change: Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer (clinicaltrials.gov) - May 19, 2013
P3, N=250, Completed, Sponsor: University of South Florida
N=500 --> 750 N=208 --> 250
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P1 trial, Metastases: Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma (clinicaltrials.gov) - May 19, 2013
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment open: Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma (clinicaltrials.gov) - May 19, 2013
P2, N=49, Recruiting, Sponsor: National Cancer Institute (NCI)
N=208 --> 250 Not yet recruiting --> Recruiting
- | vincristine / Generic mfg.
Trial completion: Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer (clinicaltrials.gov) - May 19, 2013
P3, N=250, Completed, Sponsor: University of South Florida
Not yet recruiting --> Recruiting Recruiting --> Completed
- PSMA ADC / Lantheus
New P2 trial: BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - May 16, 2013
P2, N=25, Recruiting, Sponsor: Heinrich Elinzano, MD
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Combination therapy: Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - May 15, 2013
P2, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=68 --> 45
- | onalespib (AT13387) / Otsuka
Enrollment closed, Combination therapy, Monotherapy, Metastases: A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST (clinicaltrials.gov) - May 15, 2013
P2, N=36, Active, not recruiting, Sponsor: Astex Pharmaceuticals
N=68 --> 45 Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Trial termination: Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus (clinicaltrials.gov) - May 14, 2013
P2, N=28, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Terminated; Poor accrual
- thalidomide / Generic mfg.
Trial termination: Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall (clinicaltrials.gov) - May 14, 2013
P2, N=23, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated; Poor accrual Completed --> Terminated
- Torisel (temsirolimus) / Pfizer
Trial initiation date, Combination therapy, Metastases: Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 14, 2013
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Initiation date: Oct 2006 --> Feb 2007
- MK-2206 / Merck (MSD)
Enrollment change: A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer (clinicaltrials.gov) - May 14, 2013
P2, N=29, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Oct 2006 --> Feb 2007 N=44 --> 29
- thalidomide / Generic mfg.
Enrollment change: Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall (clinicaltrials.gov) - May 14, 2013
P2, N=23, Terminated, Sponsor: National Cancer Institute (NCI)
N=44 --> 29 N=44 --> 23
- celecoxib oral / Generic mfg.
Enrollment change, Tumor cell: Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas (clinicaltrials.gov) - May 13, 2013
P1, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
N=44 --> 23 N=22 --> 120
- celecoxib oral / Generic mfg.
Clinical protocol, Enrollment open, Observational data, Retrospective data, Review, Journal, Tumor cell: Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas (clinicaltrials.gov) - May 13, 2013
P1, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
N=22 --> 120 Active, not recruiting --> Recruiting
- | Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Metastases: Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung (clinicaltrials.gov) - May 9, 2013
P2, N=35, Recruiting, Sponsor: ACORN Research, LLC
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- sildenafil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers (clinicaltrials.gov) - May 6, 2013
P1, N=50, Suspended, Sponsor: Virginia Commonwealth University
Not yet recruiting --> Recruiting N=20 --> 50
- ||| Sutent (sunitinib) / Pfizer
Trial completion, Stroma: Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib (clinicaltrials.gov) - May 6, 2013
P=N/A, N=322, Completed, Sponsor: Pfizer
N=20 --> 50 Recruiting --> Completed
- saracatinib (AZD0530) / AstraZeneca
Trial completion, Metastases: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 6, 2013
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed